{"title":"Overlapping Receptor-Based Pathogenic Cascades in Degenerative Disease: Implications Ranging from Tumor Targeting to Aging and Dementia Therapeutics","authors":"Joseph S. D’Arrigo","doi":"10.3390/ijtm4010008","DOIUrl":null,"url":null,"abstract":"Previous research has already shown that apolipoprotein (apo)A-I is adsorbed from the bloodstream onto the surface of certain colloidal lipid particles after the intravenous injection of such colloidal nanocarriers. As a result, various blood–brain barrier (BBB) scavenger receptors are targeted by these (apoA-I-coated) colloidal nanocarriers. This targeted molecular interaction is mediated/facilitated by the adsorbed apoA-I, which is then followed by receptor-mediated endocytosis and subsequent transcytosis of the nanocarrier particles across the BBB. A multifunctional combination therapy is obtained by adding the appropriate drug(s) to these biomimetic (lipid cubic phase) nanocarriers. This therapeutic targets specific cell-surface scavenger receptors, primarily class B type I (SR-BI), and crosses the blood–brain barrier. The lipid contents of artificial biomimetic (nanoemulsion) nanocarrier particles and of naturally occurring high-density lipoproteins (HDL) have been shown to be similar, which enables these nanocarrier particles to partially imitate or simulate the known heterogeneity (i.e., subpopulations or subspecies) of HDL particles. Hence, colloidal drug nanocarriers have the potential to be used in the biomedical treatment of complicated medical conditions including dementia, as well as certain elements of aging. Widespread inflammation and oxidative stress—two processes that include several pathophysiological cascades—are brought on by dementia risk factors. More recent studies suggest that proinflammatory cytokines may be released in response to a prolonged inflammatory stimulus in the gut, for example through serum amyloid A (SAA). Therefore, pharmacologically targeting a major SAA receptor implicated in the SAA-mediated cell signaling processes that cause aging and/or cognitive decline, and ultimately Alzheimer’s disease or (late-onset) dementia, could be an effective preventive and therapeutic approach.","PeriodicalId":505042,"journal":{"name":"International Journal of Translational Medicine","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Translational Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/ijtm4010008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Previous research has already shown that apolipoprotein (apo)A-I is adsorbed from the bloodstream onto the surface of certain colloidal lipid particles after the intravenous injection of such colloidal nanocarriers. As a result, various blood–brain barrier (BBB) scavenger receptors are targeted by these (apoA-I-coated) colloidal nanocarriers. This targeted molecular interaction is mediated/facilitated by the adsorbed apoA-I, which is then followed by receptor-mediated endocytosis and subsequent transcytosis of the nanocarrier particles across the BBB. A multifunctional combination therapy is obtained by adding the appropriate drug(s) to these biomimetic (lipid cubic phase) nanocarriers. This therapeutic targets specific cell-surface scavenger receptors, primarily class B type I (SR-BI), and crosses the blood–brain barrier. The lipid contents of artificial biomimetic (nanoemulsion) nanocarrier particles and of naturally occurring high-density lipoproteins (HDL) have been shown to be similar, which enables these nanocarrier particles to partially imitate or simulate the known heterogeneity (i.e., subpopulations or subspecies) of HDL particles. Hence, colloidal drug nanocarriers have the potential to be used in the biomedical treatment of complicated medical conditions including dementia, as well as certain elements of aging. Widespread inflammation and oxidative stress—two processes that include several pathophysiological cascades—are brought on by dementia risk factors. More recent studies suggest that proinflammatory cytokines may be released in response to a prolonged inflammatory stimulus in the gut, for example through serum amyloid A (SAA). Therefore, pharmacologically targeting a major SAA receptor implicated in the SAA-mediated cell signaling processes that cause aging and/or cognitive decline, and ultimately Alzheimer’s disease or (late-onset) dementia, could be an effective preventive and therapeutic approach.
先前的研究已经表明,在静脉注射某些胶体纳米载体后,载脂蛋白(载脂蛋白A-I)会从血液中吸附到这些胶体脂质颗粒的表面。因此,各种血脑屏障(BBB)清道夫受体成为这些(载脂蛋白 A-I 涂层)胶体纳米载体的靶向受体。这种靶向分子相互作用由吸附的载脂蛋白 A-I 介导/促进,然后由受体介导的内吞作用和纳米载体颗粒随后通过 BBB 的转囊作用进行。在这些仿生物(脂质立方相)纳米载体中加入适当的药物,就能获得多功能组合疗法。这种疗法针对特定的细胞表面清道夫受体,主要是 B 类 I 型(SR-BI),并能穿过血脑屏障。人工仿生(纳米乳液)纳米载体颗粒的脂质含量与天然存在的高密度脂蛋白(HDL)相似,这使得这些纳米载体颗粒能够部分模仿或模拟 HDL 颗粒的已知异质性(即亚种群或亚种)。因此,胶体药物纳米载体有可能用于包括痴呆症在内的复杂病症以及某些衰老因素的生物医学治疗。广泛的炎症和氧化应激是痴呆症风险因素导致的两个过程,其中包括多个病理生理级联。最近的研究表明,促炎细胞因子可能会在肠道长期炎症刺激下释放,例如通过血清淀粉样蛋白 A(SAA)释放。因此,针对与 SAA 介导的细胞信号传导过程有牵连的主要 SAA 受体进行药物治疗,可能是一种有效的预防和治疗方法。